Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib’s efficacy

A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

PTC Therapeutics Inc Patent Filing for Huntington’s Disease Treatment

Share this article According to GlobalData’s company profile on PTC Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. PTC Therapeutics‘s

March 29, 2024

Softball: Lyons’ star pitcher and catcher leaning on over a decade of camaraderie – The Cannabist

Lyons High School may be small, but the level of talent it possesses on the softball field has the Lions swinging like a heavyweight. The

September 19, 2024

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 – Biotech Investments

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at

March 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.